Literature DB >> 35355758

A Novel Phage Cocktail Therapy of the Urinary Tract Infection in a Mouse Model.

B Mijbel Ali1, S A Gatea Kaabi1, M A Al-Bayati1, H K Musafer1.   

Abstract

Escherichia coli (E. coli) is a major bacterial pathogen associated with many cases of serious infections, such as urinary tract infections (UTI) and meningitis intestinal. The rapid emergence of antimicrobial multidrug-resistant bacteria occurring worldwide has been attributed to the overuse of antibiotics. Alternative strategies must be developed to overcome antibiotic resistance. A promising alternative for the treatment of infections is the use of phages as antibacterial agents. A total of 90 female albino mice were randomly divided into three groups (n=30) and used for the induction of UTI. The animals were acclimatized in their cages for 24 h before inoculation and allowed to access chow and water freely. For UTI induction, the peri-urethral area was sterilized with 70% ethanol, and bacterial inoculation was then injected into the bladder through the urethra using a 24-gauge sterile Teflon catheter with an outer diameter of 0.7 mm and length of 19 mm. A single phage and a phage cocktail preparation have been evaluated for their therapeutic activity in the mouse model of chronic UTI induced by transurethral injection of two isolates of the uropathogenic E. coli 8 and E. coli 302. The results of the transurethral and intra-peritoneal injection of phage(s) that prepared on day 10 after the establishment of the mouse chronic model showed no effect of a single phage PEC80 in the treatment of UTI, whereas both administration routes of the phage cocktail preparation resulted in the clearance of bacteria from mice urine and homogenates of the urinary bladders and kidneys of the sacrificed mice after 24 h following the administration of phage cocktail dose. The high activity of the phage cocktail in the treatment of mouse chronic model of UTI is attributed to the broader host range of the phage cocktail, compared to the very narrow host range of the phage PEC80. It is concluded that the phage therapy by using phage preparations as the 25 phages cocktail evaluated in this study is a highly promising and potential alternative therapy for human UTIs.

Entities:  

Keywords:  Alternative Therapy; Drug Resistance; Phage Cocktail; Phage Therapy; UTI

Mesh:

Year:  2021        PMID: 35355758      PMCID: PMC8934106          DOI: 10.22092/ari.2021.356004.1762

Source DB:  PubMed          Journal:  Arch Razi Inst        ISSN: 0365-3439


  17 in total

1.  Antimicrobial activity of intraurethrally administered probiotic Lactobacillus casei in a murine model of Escherichia coli urinary tract infection.

Authors:  T Asahara; K Nomoto; M Watanuki; T Yokokura
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

2.  Time course and host responses to Escherichia coli urinary tract infection in genetically distinct mouse strains.

Authors:  W J Hopkins; A Gendron-Fitzpatrick; E Balish; D T Uehling
Journal:  Infect Immun       Date:  1998-06       Impact factor: 3.441

Review 3.  Visualization of the bacterial polysaccharide capsule.

Authors:  M E Bayer
Journal:  Curr Top Microbiol Immunol       Date:  1990       Impact factor: 4.291

Review 4.  The perspectives of the application of phage therapy in chronic bacterial prostatitis.

Authors:  Sławomir Letkiewicz; Ryszard Międzybrodzki; Marlena Kłak; Ewa Jończyk; Beata Weber-Dąbrowska; Andrzej Górski
Journal:  FEMS Immunol Med Microbiol       Date:  2010-08-03

5.  Adhesion, hemagglutination, and virulence of Escherichia coli causing urinary tract infections.

Authors:  L Hagberg; U Jodal; T K Korhonen; G Lidin-Janson; U Lindberg; C Svanborg Edén
Journal:  Infect Immun       Date:  1981-02       Impact factor: 3.441

Review 6.  Clinical implications of enteroadherent Escherichia coli.

Authors:  Margarita M P Arenas-Hernández; Ygnacio Martínez-Laguna; Alfredo G Torres
Journal:  Curr Gastroenterol Rep       Date:  2012-10

7.  Adapted Bacteriophages for Treating Urinary Tract Infections.

Authors:  Aleksandre Ujmajuridze; Nina Chanishvili; Marina Goderdzishvili; Lorenz Leitner; Ulrich Mehnert; Archil Chkhotua; Thomas M Kessler; Wilbert Sybesma
Journal:  Front Microbiol       Date:  2018-08-07       Impact factor: 5.640

8.  Therapeutic Characterization and Efficacy of Bacteriophage Cocktails Infecting Escherichia coli, Klebsiella pneumoniae, and Enterobacter Species.

Authors:  Prasanth Manohar; Ashok J Tamhankar; Cecilia Stalsby Lundborg; Ramesh Nachimuthu
Journal:  Front Microbiol       Date:  2019-03-21       Impact factor: 5.640

9.  Phage therapy against Pseudomonas aeruginosa infections in a cystic fibrosis zebrafish model.

Authors:  Marco Cafora; Gianluca Deflorian; Francesca Forti; Laura Ferrari; Giorgio Binelli; Federica Briani; Daniela Ghisotti; Anna Pistocchi
Journal:  Sci Rep       Date:  2019-02-06       Impact factor: 4.379

Review 10.  Applications for Bacteriophage Therapy during Pregnancy and the Perinatal Period.

Authors:  Lucy L Furfaro; Barbara J Chang; Matthew S Payne
Journal:  Front Microbiol       Date:  2018-01-11       Impact factor: 5.640

View more
  2 in total

Review 1.  Flagellotropic Bacteriophages: Opportunities and Challenges for Antimicrobial Applications.

Authors:  Nathaniel C Esteves; Birgit E Scharf
Journal:  Int J Mol Sci       Date:  2022-06-25       Impact factor: 6.208

2.  Characterization and Comparative Genomics Analysis of a New Bacteriophage BUCT610 against Klebsiella pneumoniae and Efficacy Assessment in Galleria mellonella Larvae.

Authors:  Mingfang Pu; Pengjun Han; Guangye Zhang; Yucong Liu; Yahao Li; Fei Li; Mengzhe Li; Xiaoping An; Lihua Song; Yiming Chen; Huahao Fan; Yigang Tong
Journal:  Int J Mol Sci       Date:  2022-07-21       Impact factor: 6.208

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.